Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment
Research output: Contribution to journal › Review › Research › peer-review
Standard
Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. / Cvenkel, Barbara; Kolko, Miriam.
In: Journal of Ophthalmology, Vol. 2020, 6138132, 2020.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment
AU - Cvenkel, Barbara
AU - Kolko, Miriam
PY - 2020
Y1 - 2020
N2 - Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma. However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma. Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention. Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved. The present update provides an overview of currently available IOP-lowering medications. Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed. Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.
AB - Glaucoma is a neurodegenerative disease characterized by progressive loss of retinal ganglion cells and their axons. Lowering of intraocular pressure (IOP) is currently the only proven treatment strategy for glaucoma. However, some patients show progressive loss of visual field and quality of life despite controlled IOP which indicates that other factors are implicated in glaucoma. Therefore, approaches that could prevent or decrease the rate of progression and do not rely on IOP lowering have gained much attention. Effective neuroprotection has been reported in animal models of glaucoma, but till now, no neuroprotective agents have been clinically approved. The present update provides an overview of currently available IOP-lowering medications. Moreover, potential new treatment targets for IOP-lowering and neuroprotective therapy are discussed. Finally, future trends in glaucoma therapy are addressed, including sustained drug delivery systems and progress toward personalized medicine.
U2 - 10.1155/2020/6138132
DO - 10.1155/2020/6138132
M3 - Review
C2 - 32774906
AN - SCOPUS:85089309524
VL - 2020
JO - Journal of Ophthalmology
JF - Journal of Ophthalmology
SN - 2090-004X
M1 - 6138132
ER -
ID: 249157796